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S-1, a novel oral fluoropyrimidine, is an effective therapeutic agent for gastric cancer. Herein, we report a case with 
locally advanced gastric cancer that achieved a curative resection after S-1 monotherapy as neoadjuvant treatment. 
A 68-year-old man was diagnosed with gastric cancer and massive lymphadenopathy involving the perigastric, celiac 
axis and splenic hilum. His clinical stage was cT3N2H0P0M0. Considering his relatively poor performance (ECOG 2, 
severe weight loss) and advanced age, we started the patient on S-1 monotherapy at a dose of 35 mg/m2 bid for 
4 consecutive weeks followed by a 2-week rest. Follow-up study after 4 treatment cycles revealed disappearance of 
the lymphadenopathy of the perigastric and celiac axis with diminished extension of the stomach mass. The patient 
had a partial response (PR) with a 72% tumor reduction, according to the Response Evaluation Criteria in Solid 
Tumors (RECIST). His performance status was improved to an ECOG 1 and he gained 7 kg. A curative (R0) resection 
was achieved with a radical total gastrectomy and D2 dissection. The pathological stage was pT3N2M0, stage IIIB. In 
conclusion, S-1 neoadjuvant chemotherapy aided in the treatment of gastric cancer in this patient. 
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INTRODUCTION
Surgery is the main treatment strategy for gastric cancer; 
only R0 resection anticipates a potential cure. The prognosis of 
initially unresectable gastric cancer is poor; approximately 50% 
of patients have recurrent disease after a curative resection. 
This suggests that micrometastases are already present, in 
many cases, at the time of surgery1). Neoadjuvant chemo-
therapy has been attempted for the treatment of gastric cancers 
in patients with advanced T and N stage disease for the 
purpose of downstaging, improving resectability and survival2). 
Several neoadjuvant trials have been reported to provide such 
benefits. Several regimens containing cisplatin, anthracyclines 
and methotrexate are the main chemotherapeutic options. 
These regimens have demonstrated a response rate (RR) of 3
4～69% and a resectability of 36～60%, with a median survival 
of 16～28 months for initially unresectable or stage III-IV cases. 
However, in 19～33% of patients, the associated adverse 
effects of up to grade 3-4 have impeded the use of these 
agents3-6). Therefore, the selection of patients with a good 
performance status is the first consideration for effective 
neoadjuvant chemotherapy.
S-1 is a fourth-generation oral fluoropyrimidine based on the 
combination of tegafur with two biochemical modulators, 
5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate 
(Oxo). S-1 mimics the protracted continuous infusion of 
The Korean Journal of Internal Medicine : Vol. 23, No. 1, March 200838
Figure 1. Initial endoscopic and radiological findings, (A) Endoscopy 
demonstrating a diffuse-infiltrative lesion at the great curvature of the 
upper body of the stomach. (B) Microscopic findings of adenoc-
arcinoma with poor lumen formation (H&E, ×400). (C-E) Abdominal- 
pelvic computed tomography (CT) showing a malignant mass in the 
stomach (arrow) (D), and multiple metastatic lymph nodes in the 
perigastric, upper retroperitoneum close to celiac axis (long arrow) 
(E), and splenic hilum (thick arrow) (C).
5-fluorouracil (5-FU) with enhanced efficacy and safety7). One 
earlier and two more current, phase II trials with monotherapy 
for advanced gastric cancer, in Japan, achieved a remarkable 
RR of 45% and 54% respectively. These results are consistent 
with the commonly used combination regimens containing 
cisplatin or anthracyclines8, 9). S-1 is also known to have less 
toxicity than other active agents in the treatment of gastric 
cancer. Nevertheless, there are only a few reports evaluating its 
efficacy for neoadjuvant treatment. In retrospective analyses, 
S-1 in combination with cisplatin achieved a RR of 44% and 
79% and a downstaging rate of 47% and 85%, respectively10, 11). 
Furthermore, S-1 monotherapy as neoadjuvant treatment has 
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Figure 2. Follow-up endoscopic and radiological findings after 4 cycles of S-1 treatment. (A) Endoscopy demonstrating a reduced 
stomach mass. (B-D) Abdominal-pelvic CT showing disappearance of the lymph node enlargement around the perigastric area and celiac 
axis (D), and also diminished splenic hilar lymph nodes (long arrow) (B) along with a decreased stomach mass (C).
recently been reported to induce a pathologically complete 
response (CR)12, 13) and curative resection. Based on these data, 
we report herein S-1 monotherapy as neoadjuvant treatment in 
a patient with locally advanced gastric cancer and poor 
performance status who achieved a curative resection. 
CASE REPORT
A 68-year-old man with epigastric pain, anorexia and general 
weakness for 6 months was admitted to our hospital. He lost 9 
kg in the last 6 months (12% loss). There was neither history of 
pre-existing chronic disease nor a family history of gastric 
cancer. His performance status was 2 according to the criteria 
of the Eastern Cooperative Oncology Group (ECOG).
Endoscopic examination demonstrated a diffuse-infiltrative 
lesion along the great curvature of the upper body of the 
stomach; the biopsy confirmed a moderately differentiated 
adenocarcinoma (Figure 1A, 1B). Abdominal-pelvic computed 
tomography (CT) showed a gastric cancer with massive lymph 
node enlargement in the perigastric area, upper retroperitoneum 
close to the celiac axis and the splenic hilum with no evidence 
of distant or peritoneal metastases (Figure 1C, 1D, 1E). The 
clinical stage of the patient was cT3N2H0P0M0 according to the 
staging system of the Japanese Gastric Cancer Association 
(JGCA).
Neoadjuvant chemotherapy was considered for this patient 
because of the advanced nodal involvement. However, 
significant weight loss, advanced age and a relatively poor 
general condition prevented full-dose administration of a 
multi-drug systemic chemotherapy regimen. Alternately, we 
planned S-1 monotherapy at a dose of 35 mg/m2 twice a day 
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Figure 3. Microscopic findings of the resected stomach showing 
transmural involvement of the tumor and a minor pathological 
response; more than 50% of the tumor bed is composed of tumor 
cells, according to Becker's criteria (H&E, ×400).
for 4 consecutive weeks followed by a 2-week resting period.
Follow-up endoscopy after 4 cycles showed a decrease in 
the extent of infiltrative lesions of the stomach (Figure 2A). The 
CT scan demonstrated the disappearance of lymph node 
enlargement around the perigastric area, celiac axis and also a 
decrease in the size of the splenic hilar lymph nodes along with 
a reduction in the stomach mass (Figure 2B, 2C, 2D). According 
to the RECIST criteria, a PR with a 72% decrease of the target 
lesions (sum of target lesion, 90 mm to 26 mm) was achieved. 
During the 4 cycles of treatment, there was no treatment delay 
or dose reduction due to adverse events. The patient had grade 
1 fatigue and nausea and grade 2 skin rashes without any 
grade 3-4 toxicity. The performance status improved to ECOG 
1 after the administration of S-1 and the patient gained 7 kg of 
body weight. The diagnostic laparoscopy showed a serosa- 
involving lesion on the upper body of the stomach extending 
from the anterior to the posterior wall with severe adhesions 
and surrounding tissues. 
A radical total gastrectomy with D2 lymph node dissection 
and combined splenectomy were performed. Macroscopically, 
the excised specimen showed a diffuse infiltrative lesion with 
serosal surface exposure (se) measuring 180×130 mm. 
Microscopically, there was transmural involvement of the tumor 
(Figure 3). Metastatic adenocarcinoma in 12 out of 65 resected 
lymph nodes was noted. An adequate resection margin was 
obtained on both ends and there was no microscopic 
involvement at the margins identified. According to Becker's 
criteria, more than 50% of the tumor bed was composed of 
tumor cells; therefore, the pathological response was defined as 
minor14). The final pathological stage was pT3N2M0 (H0P0), 
Stage IIIB, according to both the JGCA and the American Joint 
Committee on Cancer (AJCC) systems. The postoperative CT 
scan showed no evidence of residual disease. After an 
additional 3 cycles of S-1 monotherapy were administered as 
adjuvant chemotherapy, the patient is without any evidence of 
recurrence after 6 months of follow-up. 
DISCUSSION
Neoadjuvant chemotherapy for locally advanced gastric 
cancer has several advantages. Early initiation of systemic 
therapy may result in disease downstaging, eliminate microme-
tastases and enable a curative resection. Furthermore, 
neoadjuvant chemotherapy provides prognostic information due 
to the in vivo chemosensitivity testing. However, there are also 
potential risks involved. By delaying definitive local therapy, 
treatment-resistant clones can emerge during therapy. In 
addition, considerable tumor shrinkage is required in a short 
period for the chemotherapeutic regimen to obtain effective 
downstaging with the neoadjuvant treatment. However, regimens 
with a high tumor response are usually associated with 
substantial toxicity. Therefore, neoadjuvant therapy may not be 
feasible in some circumstances such as in patients with an 
unfavorable performance status or advance age. In the clinical 
trials using cisplatin or anthracycline-based regimens, although 
downstaging was attained, only 20～54% of the patients 
completed the planned treatment. As many as one-third of the 
patients experienced grade 3-4 adverse events3-6).
Therefore, novel chemotherapeutic agents such as taxanes, 
irinotecan and oral fluoropyrimidines might be candidates for 
future neoadjuvant trials with effects on tumor shrinkage 
comparable to and more favorable toxicity profiles than 
traditional agents.
Among the above cited agents, S-1 might be a useful 
treatment option because of the results of several phase II trials 
on advanced gastric cancer. There are a few reports on S-1 in 
the neoadjuvant setting. Two Japanese retrospective analyses 
of S-1, in combination with cisplatin as neoadjuvant treatment in 
stage III-IV disease, achieved a RR of 44% and 79% and a 
downstaging rate of 47% and 85%, respectively. However, these 
high responses are mainly due to a high PR not a pathological 
CR possibly implicating a survival benefit10, 11). Recently, 
preoperative administration of S-1 alone has been shown to 
induce favorable responses in patients in poor clinical condition. 
The total disappearance of peritoneal dissemination was 
observed with S-1 and cisplatin, and there was a pathological 
CR in a 78-year old patient who was treated with S-1 alone12). 
Our selection of S-1 in the present case was based on these 
findings. Our patient was not a candidate for full-dose 
multi-drug systemic chemotherapy due to his poor health 
Jong Yul Jung, et al : S-1 Monotherapy as a Neoadjuvant Treatment 41
status. Although downstaging was not observed in our case, 
probably due to a very large initial tumor burden, there was 
marked resolution of the massive lymphadenopathy around the 
celiac axis. This is consistent with other phase II studies on S-1 
monotherapy that reported a higher efficacy for the abdominal 
lymph nodes (75%) compared to the primary gastric mass 
(28%) or visceral organs (30%)9).
Another aspect of neoadjuvant chemotherapy to consider is 
safety, which in turn is associated with treatment compliance. In 
this respect, S-1 has an advantage with favorable toxicity 
profiles compared to other agents. Neutropenia and anemia 
were the main adverse events reported in Asian patients9, 15) 
and the neoadjuvant combination with cisplatin showed only 7% 
of cases with grade 3-4 adverse events10, 11). Our patient 
finished the treatment without significant toxicity or dose 
reduction. Moreover, the patient reported a sense of well being, 
had an improved appetite and gained weight. Therefore, S-1 
monotherapy was safe and effective treatment for this patient 
and might be considered in the future as neoadjuvant treatment 
for gastric cancer. In conclusion, the results of this case study 
suggest that S-1 might be a safe and effective treatment option 
for neoadjuvant chemotherapy in locally advanced gastric 
cancer, especially when accompanied byperigastric lymphade-
nopathy and a poor general health status in patients of 
advanced age. The role of S-1 in the neoadjuvant setting for 
the treatment of gastric cancer remains to be established by 
clinical trials.
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